跳至主要内容
临床试验/NCT01938170
NCT01938170已完成不适用

A Pilot Study to Assess the Acceptability, Tolerability, and Feasibility of Home Intranasal Administration of FluMist® by a Trained Primary Caregiver to Healthy Family Members 2 Through 17 Years of Age

University of North Carolina, Chapel Hill2 个研究点 分布在 1 个国家目标入组 41 人开始时间: 2014年9月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
41
试验地点
2
主要终点
Number of Subjects That Reported Successful Home Vaccination With no Adverse Events

研究概览

简要总结

This study will examine the feasibility of having parents and caregivers administer FluMist live intranasal vaccine to their children at home outside the traditional medical environment and without the involvement of medical personnel.

The study will recruit patients and families that are already eligible to receive the FluMist vaccine. After consent is obtained and vaccine is given to the family, they will go home to administer vaccine to other members within 24 hours. Telephone follow up within 48 hours will confirm that vaccine was given successfully and within 9-12 days to assess patient preferences for giving vaccine at home and if there were any adverse events.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
2 Years 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • The primary caregiver must be 18 years of age or older and willing to give written informed consent for study participation
  • The primary caregiver must be the parent or legal guardian of all the children in living in the household
  • All the children in the household who are 2 through 17 years of age must receive their primary care in the clinic
  • All the children in the household who are 2 through 17 years of age must have private insurance that will provide for the cost of influenza vaccination
  • There must be at least one member of the household who is 2 through 17 years of age, presenting for care in the clinic, eligible to receive Live Attenuated Influenza Vaccine (LAIV) and whose primary care giver is willing to administer LAIV to them in the clinic with supervision
  • There must be at least one family member of the household who is 2 through 17 years of age, not presenting for care in the clinic, eligible to receive LAIV and whose primary care giver is willing to administer LAIV to them in the in-home setting
  • There must be a working refrigerator in the household
  • The primary caregiver must have a working telephone number and be willing to be contacted for study follow-up by telephone or e-mail
  • The primary caregiver is available for the entire study period - 12 days following the last dose of LAIV to be administered to a child
  • The primary caregiver must agree to complete a 30 minute post vaccination assessment and an 8 day diary following vaccination for each child receiving LAIV.

排除标准

  • Children in the family receive vaccine through Vaccines for Children program

结局指标

主要结局

Number of Subjects That Reported Successful Home Vaccination With no Adverse Events

时间窗: 0-12 days

We will assess the tolerability of giving the FluMist nasal vaccine at home by parents/caregivers to their children by performing telephone survey follow up. We will ask parents at both 24-48 hours and at 9-12 days after study visit and enrollment about any difficulties in giving FluMist at home and any adverse events encountered when giving FluMist at home.

次要结局

  • Number of Subjects That Reported Ability to Successfully Administer FluMist Vaccine at Home(0-12 days)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验